Current Editions
A new standard for swift entry
Editor's Commentary
CDER director says FDA is re-evaluating cancer endpoints and moving to speed clinical trial regulation, including IND process
Politics, Policy & Law
Disputing legitimacy of rival bid, Pfizer has brief window to renegotiate or pursue legal, political alternatives
Deals
Fresh off a $1.2B takeout of Boston Pharma by GSK, Kornowski parlays her years in pharma BD into lessons for biotechs, on The BioCentury Show
Deals
Product Development
On BioCentury’s latest podcast: Paradigm-shifting speed of development, landmark deals, homegrown talent and a surging Hong Kong market
Emerging Company Profile
Philadelphia-based newco designing a two-part therapy for use across many solid tumor types
Data Byte
Despite pelacarsen’s first-mover advantage, olpasiran and lepodisiran offer speedier, longer-lasting Lp(a) reduction with less frequent dosing
Decisions expected for Arrowhead siRNA, Kura AML small molecule
Discovery & Translation
BioCentury’s translational roundup also highlights five papers on delivery advances
Regulation
Tidmarsh said FDA has launched an initiative to assess surrogate endpoints for accelerated approval in cancer and other diseases
Deals
The pharma’s $12B Avidity takeout delivers trio of programs for muscular dystrophies, all nearing regulatory submission; cardio spinout to follow
Finance
BrightGene, NovaBridge, Alebund, Ribo and Lupeng all seek HKSE offerings; MapLight gives back its gains; and more
Biopharma Stock Performers
Use BioCentury's interactive dashboard to view top-performing biopharma stocks for the day and the week.
Product Development
Deals
Management Tracks
BioCentury ISSN 1097-7201